Fig. 4From: A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeuticCellular cytotoxicity assay at different effector (PBMCs) and target cells (293KDR) ratios. Untreated PBMCs without exogenous cytokines served as control. Experiments were repeated three times and the results are presented as mean ± SD. Multiple comparisons were performed using 2-way ANOVABack to article page